{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VELCADE+1.3+mg%2Fm%5E2", "query": { "intervention": "VELCADE 1.3 mg/m^2" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VELCADE+1.3+mg%2Fm%5E2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T09:18:05.170Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01323920", "title": "Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 35, "start_date": "2011-05", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01323920" }, { "nct_id": "NCT00083226", "title": "Doxorubicin and Bortezomib in Treating Patients With Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer" ], "interventions": [ { "name": "doxorubicin", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-03", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-10-30", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083226" }, { "nct_id": "NCT01420926", "title": "Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 165, "start_date": "2011-11-16", "completion_date": "2021-04-01", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 53, "location_summary": "Mountain View, California • Hartford, Connecticut • Lewes, Delaware + 41 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420926" }, { "nct_id": "NCT02195479", "title": "A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Daratumumab IV", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 706, "start_date": "2014-12-09", "completion_date": "2024-08-07", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 10, "location_summary": "California City, California • Corona, California • Fountain Valley, California + 7 more", "locations": [ { "city": "California City", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02195479" }, { "nct_id": "NCT00703664", "title": "Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2008-07-09", "completion_date": "2017-12-01", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 12, "location_summary": "Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00703664" }, { "nct_id": "NCT00869323", "title": "Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2009-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • St Louis, Missouri", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869323" }, { "nct_id": "NCT00315757", "title": "Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Mapatumumab", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2006-05", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2013-08-08", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • La Jolla, California • Lecanto, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Lecanto", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00315757" }, { "nct_id": "NCT00571493", "title": "VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 42, "start_date": "2006-04-14", "completion_date": "2014-11-01", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571493" }, { "nct_id": "NCT01769209", "title": "Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia (ALL)", "Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)", "Recurrent Adult Acute Lymphoblastic Leukemia (ALL)", "T-cell Adult Acute Lymphoblastic Leukemia (ALL)" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride (HCl)", "type": "DRUG" }, { "name": "PEG-Asparaginase", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-03", "completion_date": "2017-07-04", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769209" }, { "nct_id": "NCT01485835", "title": "A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ganetespib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2012-01", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-25T09:18:05.170Z", "location_count": 8, "location_summary": "Denver, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485835" } ] }